Julia D Suerth
Overview
Explore the profile of Julia D Suerth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suerth J, Morgan M, Kloess S, Heckl D, Neudorfl C, Falk C, et al.
J Mol Med (Berl)
. 2023 Dec;
102(1):143-145.
PMID: 38057608
No abstract available.
2.
Baron Y, Sens J, Lange L, Nassauer L, Klatt D, Hoffmann D, et al.
Mol Ther Nucleic Acids
. 2022 Feb;
27:810-823.
PMID: 35141043
DNA-modifying technologies, such as the CRISPR-Cas9 system, are promising tools in the field of gene and cell therapies. However, high and prolonged expression of DNA-modifying enzymes may cause cytotoxic and...
3.
Labenski V, Suerth J, Barczak E, Heckl D, Levy C, Bernadin O, et al.
Biomaterials
. 2016 May;
97:97-109.
PMID: 27162078
Primary human T lymphocytes represent an important cell population for adoptive immunotherapies, including chimeric-antigen and T-cell receptor applications, as they have the capability to eliminate non-self, virus-infected and tumor cells....
4.
Hubner J, Hoseini S, Suerth J, Hoffmann D, Maluski M, Herbst J, et al.
Mol Ther
. 2016 May;
24(7):1216-26.
PMID: 27138041
Retroviral engineering of hematopoietic stem cell-derived precursor T-cells (preTs) opens the possibility of targeted T-cell transfer across human leukocyte antigen (HLA)-barriers. Alpharetroviral vectors exhibit a more neutral integration pattern thereby...
5.
Suerth J, Morgan M, Kloess S, Heckl D, Neudorfl C, Falk C, et al.
J Mol Med (Berl)
. 2015 Aug;
94(1):83-93.
PMID: 26300042
Unlabelled: Natural killer (NK) cells play an important role in tumor immunotherapy with their unique capability of killing transformed cells without the need for prior sensitization and without major histocompatibility...
6.
Coci E, Maetzig T, Zychlinski D, Rothe M, Suerth J, Klein C, et al.
Curr Gene Ther
. 2015 May;
15(3):245 - 254.
PMID: 25963902
The article entitled “Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich Syndrome”, by E. G. Coci1, T. Maetzig, D. Zychlinski, M. Rothe, J. D. Suerth, C. Klein and...
7.
Glienke W, Esser R, Priesner C, Suerth J, Schambach A, Wels W, et al.
Front Pharmacol
. 2015 Mar;
6:21.
PMID: 25729364
In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against...
8.
Suerth J, Labenski V, Schambach A
Viruses
. 2014 Dec;
6(12):4811-38.
PMID: 25490763
Gene therapy using integrating retroviral vectors has proven its effectiveness in several clinical trials for the treatment of inherited diseases and cancer. However, vector-mediated adverse events related to insertional mutagenesis...
9.
Kuehle J, Turan S, Cantz T, Hoffmann D, Suerth J, Maetzig T, et al.
Mol Ther
. 2014 Jan;
22(5):919-28.
PMID: 24434935
Methods for generating induced pluripotent stem cells (iPSCs) for disease modeling and cell therapies have progressed from integrating vectors to transient delivery of reprogramming factors, avoiding permanent genomic modification. A...
10.
Brugman M, Suerth J, Rothe M, Suerbaum S, Schambach A, Modlich U, et al.
Hum Gene Ther Methods
. 2013 Feb;
24(2):68-79.
PMID: 23384086
Retroviral gene transfer has proven therapeutic potential in clinical gene therapy trials but may also cause abnormal cell growth via perturbation of gene expression in the locus surrounding the insertion...